The ink is not dry on Mylan NV’s settlement with the US Department of Justice (DOJ) regarding EpiPen (epinephrine) rebates to Medicaid – and, in fact, the agreement still is being written – but investors are relieved that the company has avoided a major investigation and a larger penalty, despite lingering risks.
Mylan’s stock jumped 8.2% to close at $38.87 per share on Oct. 10 following the company’s announcement after the stock...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
